期刊
CANCERS
卷 14, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/cancers14051241
关键词
acute myeloid leukemia (AML); chimeric antigen receptor (CAR)-T cells; co-stimulatory domains; preclinical model; single-chain variable fragment (scFv)
类别
CAR-T cell therapy is a promising cancer treatment method, but it also brings about some immune-related toxicities. Impressive results have been achieved in treating B cell hematological malignancies, but further research is needed for other hematological malignancies. This article summarizes the findings from preclinical and human studies of CAR-T cell therapy and discusses new treatment targets.
Engineered T cells expressing chimeric antigen receptors (CARs) on their cell surface can redirect antigen specificity. This ability makes CARs one of the most promising cancer therapeutic agents. CAR-T cells for treating patients with B cell hematological malignancies have shown impressive results. Clinical manifestation has yielded several trials, so far five CAR-T cell therapies have received US Food and Drug Administration (FDA) approval. However, emerging clinical data and recent findings have identified some immune-related toxicities due to CAR-T cell therapy. Given the outcome and utilization of the same proof of concept, further investigation in other hematological malignancies, such as leukemias, is warranted. This review discusses the previous findings from the pre-clinical and human experience with CAR-T cell therapy. Additionally, we describe recent developments of novel targets for adoptive immunotherapy. Here we present some of the early findings from the pre-clinical studies of CAR-T cell modification through advances in genetic engineering, gene editing, cellular programming, and formats of synthetic biology, along with the ongoing efforts to restore the function of exhausted CAR-T cells through epigenetic remodeling. We aim to shed light on the new targets focusing on acute myeloid leukemia (AML).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据